3-dimethylamino-propane-1-sulfonyl chloride Hydrochlorid | 118646-42-7

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 磺酰卤
• 英文名称: 3-dimethylamino-propane-1-sulfonyl chloride Hydrochlorid
• 英文别名: 3-(dimethylamino)-1-propanesulfonyl chloride hydrochloride；3-(Dimethylamino)propane-1-sulfonyl chloride hydrochloride；3-(dimethylamino)propane-1-sulfonyl chloride;hydrochloride
• CAS: 118646-42-7
• 化学式: C₅H₁₂ClNO₂S*ClH
• 分子量: 222.136
• InChiKey: BYKKHSIDBWTCTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.93
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  氨基亚氨基硫代甲基氢碘酸 、 3-dimethylamino-propane-1-sulfonyl chloride Hydrochlorid 在 三乙胺 作用下， 以 丙酮 为溶剂， 以20%的产率得到methyl<<3-(dimethylamino)propyl>sulfonyl>carbamimidothioate
  参考文献：
  名称：

  Cardiotonic agents 4. Dimaprit analogues as potential cardiovascular selective H2-agonists

  摘要：

  DOI：

  10.1016/0223-5234(88)90013-x
• 作为产物：
  描述：

  3-Dimethylamino-1-propanthiol-hydrochlorid 、 氯 生成 3-dimethylamino-propane-1-sulfonyl chloride Hydrochlorid
  参考文献：
  名称：

  OWENS, ALBERT H.;GOEHRING, R.;LAMPE, JOHN W.;ERHARDT, PAUL W.;LUMMA, WILL+, EUR. J. MED. CHEM., 23,(1988) N 3, C. 295-300

  摘要：

  DOI：

文献信息

• Hydrazine derivatives
  申请人：Hoffmann-La Roche Inc..

  公开号：US06265446B1

  公开（公告）日：2001-07-24

  Hydrazine derivatives of the formula wherein R1 represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl, R2 represents heterocyclyl or NR5R6, R3 represents hydrogen, lower alkyl, halo-lower alkyl, cyano-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, heterocyclyl-lower alkyl, heterocyclylcarbonyl-lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, heteroaryl or aryl-lower alkyl, R4 represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a grouping of the formula -Z-aryl, -Z-heterocyclyl or —(CH2)n—, CH═CR7R8, R5 and R6 each independently represent hydrogen or lower alkyl, R7 and R8 each independently represent hydrogen or lower alkyl or R7 and R8 together represent lower alkylene in which one CH2 group is optionally replaced by a hetero atom, X and Z each represent a spacer group, and n stands for 0, 1 or 2, and their pharmaceutically acceptable salts thereof, inhibit the release of tumor necrosis factor alpha (TNF-&agr;) from cells. They can be used as medicaments, especially in the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumors, cachexia, cardiovascular diseases, fever, haemorrhage and sepsis.

  氢肼衍生物的化学式如下： 其中R1代表较低的烷基、较低的烯基、较低的环烷基、较低的环烷基-较低的烷基、芳基或芳基-较低的烷基，R2代表杂环烷基或NR5R6，R3代表氢、较低的烷基、卤代-较低的烷基、氰基-较低的烷基、羟基-较低的烷基、氨基-较低的烷基、较低的烷氧基-较低的烷基、较低的烷氧羰基-较低的烷基、较低的环烷基-较低的烷基、芳基-较低的烷基、杂环烷基-较低的烷基、杂环烷基羰基-较低的烷基、较低的烯基、较低的炔基、较低的环烷基、芳基、杂芳基或芳基-较低的烷基，R4代表较低的烷基、较低的烯基、较低的环烷基、较低的环烷基-较低的烷基或化学式-Z-芳基、-Z-杂环烷基或—(CH2)n—、CH═CR7R8的基团，R5和R6各自独立地代表氢或较低的烷基，R7和R8各自独立地代表氢或较低的烷基，或者R7和R8一起代表较低的烷基，其中一个CH2基团可选择性地被一个杂原子取代，X和Z各自代表一个间隔基团，n代表0、1或2，以及它们的药学上可接受的盐，可以抑制细胞释放肿瘤坏死因子α（TNF-α）。它们可用作药物，特别是用于治疗炎症和自身免疫性疾病、骨关节炎、呼吸道疾病、肿瘤、消瘦症、心血管疾病、发热、出血和败血症。
• [EN] 4—(1H— IMIDAZOL— 5— YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS<br/>[FR] 4-(1H-IMIDAZOL-5-YL)-1H-PYRROLO [2,3-B] PYRIDINES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT DE LEUCÉMIES, DE LYMPHOMES ET DE TUMEURS SOLIDES
  申请人：UNIV MASARYKOVA

  公开号：WO2019185631A1

  公开（公告）日：2019-10-03

  The present invention relates to novel 4-(1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridine compounds which are useful in the treatment of lymphomas, leukaemias, and solid tumors.

  本发明涉及一种新型的4-(1H-咪唑-5-基)-1H-吡咯[2,3-b]吡啶化合物，可用于治疗淋巴瘤、白血病和实体肿瘤。
• TRIAZOLOPYRIDAZINE
  申请人：ENGELHARDT Harald

  公开号：US20140135336A1

  公开（公告）日：2014-05-15

  Disclosed are compounds of general formula (I) wherein the groups R 1 to R 3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

  揭示了一般式(I)的化合物，其中基团R1至R3具有索赔和说明中所给的含义。本发明的化合物适用于治疗以细胞过度或异常增殖为特征的疾病，包括含有这些化合物的药物制剂以及它们作为药物的用途。
• [EN] TRIAZOLOPYRIDAZINE<br/>[FR] DÉRIVÉS TRIAZOLOPYRIDAZINES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014076146A1

  公开（公告）日：2014-05-22

  The present invention encompasses compounds of general formula (I), wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

  本发明涵盖了一般式(I)中的化合物，其中基团R1至R3具有声明和规范中给出的含义。本发明的化合物适用于治疗由过度或异常细胞增殖特征的疾病，包括含有这些化合物的药物制剂以及它们作为药物的用途。
• [EN] SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS<br/>[FR] COMPOSÉS DE QUINOLÉINE SUBSTITUÉS DE MANIÈRE SÉLECTIVE
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2015057655A1

  公开（公告）日：2015-04-23

  Embodiments of the disclosure relate to selectively substituted quinoline compounds of formula (I) that act as antagonists or inhibitors for Toll -like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

  本公开的实施例涉及选择性取代喹啉化合物（I）的公式，其作为Toll样受体7和/或8的拮抗剂或抑制剂，并且它们在制药组合物中的使用对于系统性红斑狼疮（SLE）和狼疮性肾炎的治疗有效。